LGD-4033 - 10MG/1ML | 30ML Bottle with dropper

LGD 4033, also known as ligandrol, is a non-steroidal selective androgen receptor modulator (SARM). Unlike steroids, SARM selectively binds to androgen receptors in muscle and bone and only exerts anabolic effects. Ligandrol is prohibited by the World Anti Doping Agency(WADA) as it can increase lean body mass and enhance performance.

It was first developed by ligand pharmaceuticals for the treatment of conditions like muscle wasting and osteoporosis. Later on, it was licensed to Viking Therapeutics. Research shows that ligandrol is associated with a better side effect profile as compared to steroids, which makes it a subject of interest for researchers. At Element Sarms, LGD 4033 for sale is restricted to research and educational purposes.

From Pubchem

IUPAC Name:4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
Synonym: 1165910-22-4, Ligandrol
Molecular Formula: C14H12F6N2O
Molecular Weight: 338.25 g/mol
CAS Number: 1165910-22-4
PubChem CID: 44137686

1. Ligandrol and Muscle Health

Ligandrol has been shown to improve muscle growth and enhance performance. Muscle health and function decline with hormonal change. A study was conducted to assess the effect of ligandrol on muscles in the ovariectomized rat model. Removal of ovaries causes decreasing levels of hormones associated with deteriorating muscle function. Results found that ligandrol treatment resulted in increased capillary density, elevated citrate synthase and lactate dehydrogenase activity as compared to the untreated group. Further, 4 mg ligandrol resulted in higher intramuscular fat content in the quadriceps femoris muscle [1].

Similarly, one randomized controlled trial conducted on humans found that ligandrol improved lean muscle mass and strength in a dose-dependent manner [2].

2. Ligandrol and Osteoprosis

Liagrandol positively impacts bone mineral density. One study looked at the effect of LGD-4033 in the osteoporosis model of ovariectomized rats. Subjects received ligandrol at a dose of 0.03, 0.3, or 3 mg/kg body weight. The results that rats treated with a 3 mg dose experienced an improvement in bone structural properties in terms of trabecular number in the femur, lumbar vertebral bodies, and tibia. Further, it was associated with an increase in heart and uterus size, demanding reevaluation of its use for osteoporosis. However, low and medium doses didn’t significantly affect bone tissue and caused fewer side effects [3].

3. Ligandrol and Bone fracture

In the phase II clinical trial, researchers looked at the effect of ligandrol on patients with hip fractures. Patients were randomized to receive ligandrol doses of 0.5mg, 1mg, 2mg or placebo. The result found that the patients treated with the drug experienced an improvement in a six-minute walk in a dose-dependent manner. The group that received the highest dose observed an increase in mean distance by 22 meters compared to the control group. It also improved the bone turnover marker, serum procollagen type 1 peptide. Moreover, improvement in lean body mass and reduction in fat mass was observed [4].

4. Ligandrol and Liver Injury

Several case reports suggest the association between SARMs use and liver injury. In a case report, two young men developed liver injury after they stopped using ligandrol while on post-cycle therapy [5].

Further, one more case of liver injury was reported in a 34-year-old man after using ligandrol [6]. It is characterized by elevated levels of AST, ALT, alkaline phosphatase and bilirubin.

5. Current status of Ligandrol

Ligandrol is a non-steroidal androgen receptor modulator. It is popular among athletes for its effect on muscles. However, it’s not a well-studied SARM and is reported to cause liver injury. It is not approved by the FDA. We don’t support its unwarranted use and offer LGD 4033 purchase for research and educational purposes only. Buy LGD 4033 from Element Sarms to fulfil your research needs.

1. Roch, P.J., et al., Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model. Frontiers in Endocrinology, 2020. 11.
2. Basaria, S., et al., The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci, 2013. 68(1): p. 87-95.
3. Hoffmann, D.B., et al., Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis. Journal of Bone and Mineral Metabolism, 2023.
4. Koller, T., et al., Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. World J Clin Cases, 2021. 9(16): p. 4062-4071.
5. Barbara, M., S. Dhingra, and A.L. Mindikoglu, Ligandrol (LGD-4033)-Induced Liver Injury. ACG Case Rep J, 2020. 7(6): p. E00370.